Are you or a loved one facing stage IV or recurrent non-small cell lung cancer (NSCLC)? Stand Up To Cancer (SU2C) is supporting a clinical trial that may one day benefit not only patients with NSCLC, but potentially those with other cancer types as well.
Lung cancer is recognized by the immune system, yet many cancer treatments that unleash an immune attack on cancer cells, known as immune checkpoint inhibitors, don’t work in up to 80% of patients with NSCLC.
What is nivolumab?
Nivolumab is a type of immunotherapy that stops the tumor from repressing the immune system response. It is an antibody that binds to the body’s T cells in order to keep them turned “on” even while the tumor is trying to turn them “off.” These activated T cells (white blood cells that help your body fight disease) can then attack the cancer cells.
Tumor-infiltrating lymphocytes (TILs) are an immune treatment in which the patient’s own tumor is used to fight the disease. The patient’s tumor is harvested; then immune cells (helper and killer T cells) are isolated from the patient’s tumor, grown and then re-infused back into the patient. This type of treatment has been shown to achieve lasting and durable remissions in some other types of cancer, but has not yet been reported in lung cancer. This clinical trial will combine the TIL cancer treatment with the immune checkpoint inhibitor nivolumab to test whether the combination is safe, and to see if it will ultimately increase the patient’s tumor response rate and duration of remission.
This trial will help confirm whether a TIL immune treatment in combination with an immune checkpoint inhibitor has promise for patients with NSCLC. This trial will assess the safety of the treatment combination and lay the groundwork for future studies to better understand which TIL features produce the greatest success rate in patients. Your involvement is needed to continue this cutting-edge approach that could help improve cancer treatments for patients.
Key Insights for Participants
This trial is designed for patients who have never received a PD-1 immunotherapy treatment.
Once the tumor is harvested, it can take up to two months to grow TILs. Therefore, a patient whose condition is declining rapidly may not be the best candidate for this particular study.
Participants interested in this study must have a tumor that can be surgically removed in order to grow the TILs.
Patients with confirmed diagnosis of stage IV or recurrent NSCLC are eligible to enroll. There are additional criteria that must be met to participate, or that may prevent a patient from participating.
Key criteria are summarized below and can be found in detail on ClinicalTrials.gov. Interested patients will need to review their medical history with a clinical trial patient coordinator before they can be accepted to participate in this trial.
Female or Male
18 years and older
Stage IV or recurrent non-small cell lung cancer (NSCLC)
Eligible participants must have received no previous PD-1 treatment, or no more than five prior types of treatment (not including
Participants must have sufficient liver, kidney and blood counts to participate.
For patient safety, there must be NO evidence of an active autoimmune condition, a supplemental oxygen requirement, previous pneumonitis, heart failure, significant heart problems or other active cancers.
Participants may not have any active infections including HIV and hepatitis
Here are the locations where you can currently participate in this clinical trial. If you, a loved, or patient are interested, please contact the patient coordinator at your preferred site. The patient coordinator is there to help you understand every aspect of the clinical trial process and answer any questions you may have.
Once you contact the patient coordinator, he or she will start by reviewing your medical history with you to see whether you meet all the criteria to participate. The coordinator will then guide you through a review of the study and detailed “informed consent” documents that you are required to sign when you enroll in a clinical trial.
Tampa - Florida
Moffitt Cancer Center
Ben Creelan, MD
Patient Coordinator: Caitlyn Ward
Here are some links to informational videos and organizations that provide more information about TIL Therapy and NSCLC, and may provide information on patient support, treatment options, and current clinical trials.
Find out if there's a trial for you. Reach out today.
Even if you do not meet the requirements for this trial, there may be other trials for you. Get started with the SU2C Clinical Trial Finder, a free and confidential cancer clinical trial matching and referral service.
(Please fill out all fields and questions below to better assist you.)